Amalgam Rx Secures $20M Funding to Revolutionize Global Care Delivery with AI-Powered Precision

Amalgam Rx, a pioneering healthtech company dedicated to empowering patients and providers during every phase of care, has successfully raised US$20,000,000 in its latest round of funding. This substantial investment reinforces Amalgam Rx’s commitment to transforming the healthcare landscape by integrating innovative technology into everyday clinical workflows. With its modular Software as a Medical Device (SaMD) platform, cutting-edge electronic health record (EHR) solutions, and medical-grade AI, the company continues to redefine how patient care is delivered and managed across global healthcare settings. By partnering with life sciences companies, health plans, and providers worldwide, Amalgam Rx has built an impressive track record; its AI-powered solutions now support nearly 10 million patients across four continents and have contributed to over 70 million clinical decisions, highlighting the proven efficacy and reach of its technology. The new funding will be strategically deployed to further enhance and scale the company’s offerings, accelerate expansion into new markets, and drive significant advancements in clinical decision support systems. This infusion of capital will enable Amalgam Rx to invest in research and development, optimize and expand its digital health solutions, and further integrate its sophisticated tools within various healthcare environments—thereby helping healthcare professionals make more informed decisions faster. As the global demand for efficient, patient-centric care continues to rise, Amalgam Rx is uniquely positioned to lead this transformation. For more details on the company’s innovation and its roadmap for the future, visit www.amalgamrx.com.